The central actors in this model are B lymphocytes, the white blood cells that produce antibodies. Throughout life, the B cell compartment is governed by an elaborate series of quality-control checkpoints, often described as tolerance mechanisms, whose job is to prevent cells that recognize the body’s own molecules from surviving and maturing. During development in the bone marrow, immature B cells whose receptors bind self-antigens too strongly are either deleted, rendered inert through a state called anergy, or rescued by receptor editing, a process in which the cell reconfigures its antigen receptor to change its specificity. Later, in peripheral tissues, additional checkpoints eliminate or silence self-reactive cells that escaped the first round of screening. These mechanisms are among the most intensely studied in immunology, and classic work by Goodnow and colleagues and by Nemazee and Weigert established the cellular and genetic logic behind them.

Zouali’s first step concerns what happens to this quality-control apparatus as B cells themselves age. The review argues that aging drives a progressive, cell-intrinsic relaxation of both central and peripheral tolerance. In other words, the checkpoints do not simply disappear; they become leakier, allowing autoreactive clones that would have been purged in youth to survive and accumulate. Several lines of evidence converge on this conclusion. The diversity of the B cell repertoire shrinks markedly in old age, a change correlated with poor health status, and studies of the antibody repertoire in aged animals reveal skewing toward self-reactive specificities. Early developmental checkpoints are also vulnerable: inflammatory immune cells in aged organisms appear to impair the pre-B cell receptor checkpoint, the very gate that screens newly generated B cells, reducing the production of fresh B cells and altering the antibody repertoire in ways that favor autoreactivity.

Critically, this relaxation is not a random decay. The review emphasizes that intrinsic B cell aging involves deep remodeling of the cell’s transcriptional programs, epigenetic landscape, metabolism, and signaling circuitry. Epigenetic modifications, such as changes in DNA methylation, are known to be dynamically reshaped during B cell responses, and epigenetic dysregulation is increasingly implicated in autoimmune pathogenesis. B cells from elderly donors display distinct metabolic phenotypes, with altered mitochondrial activity and nutrient sensing that change how these cells respond to stimulation. Signaling through the B cell receptor and through innate immune receptors such as Toll-like receptors also changes with age, tilting the balance of intracellular pathways toward survival and activation of cells that would previously have been eliminated. Together, these changes durably reprogram B cell responsiveness, establishing a substrate on which autoimmunity can later build.

The second step of the model introduces inflammaging, the chronic, low-grade inflammatory state that characterizes old age. Elevated levels of inflammatory cytokines circulate throughout the aging body, driven by sources as varied as senescent cells, dysfunctional mitochondria, an altered gut microbiota, and persistent viral infections such as cytomegalovirus. Rather than uniformly activating the entire B cell compartment, Zouali argues that inflammaging acts as a selective pressure, preferentially expanding particular inflammation-adapted B cell subsets that are uniquely equipped to thrive under chronic inflammatory conditions. The most prominent of these are age-associated B cells, known as ABCs, and related double-negative 2, or DN2, populations, both characterized by expression of the transcription factor T-bet and the marker CD11c.

These inflammation-adapted subsets are far from innocuous bystanders. Landmark studies showed that Toll-like receptor 7 signaling drives the accumulation of a novel CD11c-positive B cell population that is important for the development of autoimmunity, and that unregulated Toll-like receptor 7 responses generate distinct effector B cells contributing to pathogenic outcomes in systemic lupus erythematosus. In humans, T-bet-positive B cells are induced by viral infections and can dominate antibody responses, illustrating how antiviral programs and autoimmune risk can become entangled. Single-cell analyses of patients with acute lupus have revealed massive expansions of antibody-secreting cells that are diverse in origin and rich in autoreactive specificities, and DN2 B cells have been identified as the major synovial plasma cell precursors in rheumatoid arthritis joints. Elevated expression of BAFF, a survival factor for B cells, in early rheumatoid arthritis further illustrates how inflammatory milieus tilt the competition among B cell subsets.

A key insight of the two-step model concerns the route by which these cells differentiate. In a healthy immune response, B cells that encounter antigen typically migrate into germinal centers, specialized structures where antibody genes undergo mutation and selection, and where tolerance checkpoints operate to weed out cells that have acquired self-reactivity. The review proposes that the synergy between intrinsic B cell aging and inflammaging instead promotes extrafollicular differentiation, a faster, less regulated pathway in which activated B cells become antibody-secreting cells outside germinal centers. Because this route bypasses key germinal-center tolerance checkpoints, it enriches for autoreactive B cell states, allowing self-reactive clones that survived the first-step relaxation to expand and differentiate without encountering the final quality controls. Work defining the extrafollicular B cell response roadmap has highlighted how distinct this pathway is from canonical germinal-center immunity, and how readily it can generate pathogenic antibodies.

The model also explains why conventional B cell-depleting therapies sometimes fall short in older patients. Age-associated B cells are notably resilient: recent studies in murine lupus models demonstrated that T-bet-positive, CD11c-positive ABCs resist ablation by therapies targeting BLyS, the survival factor BAFF, and CD20, the molecule targeted by rituximab. Chronic B cell receptor signaling has been shown to be critical for the differentiation of anergic B cells into age-associated B cells during aging and autoimmunity, suggesting that these cells adopt activation states that shield them from current interventions. Understanding the two-step logic of their generation therefore points toward more selective therapeutic targets, including the innate signaling pathways, metabolic programs, and epigenetic regulators that distinguish inflammation-adapted B cells from the protective repertoire that vaccines and therapies must preserve.

The broader implications reach beyond autoimmunity. Immunosenescence and inflammaging have been implicated in the hyperinflammatory syndrome seen in some older patients with COVID-19, and the same B cell subsets that promote autoreactivity can also shape responses to tumors, since tumor-infiltrating B cells are now recognized as a widespread feature of human cancers. Age-related changes in the immune system also pose major challenges for the development of vaccines tailored to older adults, because the very shifts that favor autoreactive, inflammation-adapted clones undermine the naive and germinal-center responses on which most vaccines depend. A framework that links B cell-intrinsic aging with inflammaging thus offers a conceptual bridge between immune aging, autoimmunity, vaccine failure, and chronic inflammatory disease.

Zouali’s two-step model does not claim that either mechanism alone is sufficient. Intrinsic aging establishes susceptibility by loosening tolerance and accumulating autoreactive clones, while inflammaging supplies the selective pressure and the activation signals that amplify pathogenic B cell programs into clinically meaningful autoimmunity. Disentangling these contributions experimentally, and identifying which of the transcriptional, epigenetic, metabolic, or signaling changes are druggable, now stands as the central challenge. If the model holds, the payoff could be a new generation of interventions that restore tolerance in the aging immune system without dismantling its remaining defenses, turning one of biology’s most stubborn paradoxes into a tractable therapeutic problem.

Subject of Research: Age-associated B cell autoreactivity driven by intrinsic B cell aging and inflammaging

Article Title: A two-step model of age-associated autoreactivity: B cell–intrinsic aging meets inflammaging

Article References: A two-step model of age-associated autoreactivity: B cell–intrinsic aging meets inflammaging. (n.d.). https://doi.org/10.1007/s11357-026-02557-5

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02557-5

Keywords: immunosenescence, B cell tolerance, inflammaging, age-associated B cells, autoreactivity, autoimmunity, extrafollicular differentiation, T-bet, Toll-like receptor 7, epigenetics, B cell metabolism, geroscience